IPOs and Secondaries

IPOs and Secondaries Articles

Viamet Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Merus has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
SecureWorks has priced its planned initial public offering of 9 million class A shares in a range of $15.50 to $17.50 per share.
There was only one initial public offering (IPO) on last week’s calendar, and miracle of miracles, it was completed. The not so good news is that it sold far below its expected price range and...
MGM Growth Properties has filed documents with the SEC to sell 50 million shares of common stock to raise more than $1 billion in an initial public offering (IPO).
American Renal Associates Holdings has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
GMS has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Aeglea BioTherapeutics entered the market quietly on Thursday morning, with pricing below the expected range of $16 to $18 per share.
inVentiv has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Yintech Investment Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Nutanix has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
BATS Global Markets intends to price more than 11 million shares in the range of $17 to $19 for an initial public offering valued up to more than $244 million.
McGraw-Hill Education has amended its filing with the Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Turning Point Brands has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Just like the entire first quarter, the last week of March was a disappoint for initial public offering (IPO) investors. No offering made it out, and the one that had been scheduled to try, Sensus...